NO20021625L - Synergistiske kombinasjoner av en NK1 reseptor antagonist og en GABA strukturell analog - Google Patents
Synergistiske kombinasjoner av en NK1 reseptor antagonist og en GABA strukturell analogInfo
- Publication number
- NO20021625L NO20021625L NO20021625A NO20021625A NO20021625L NO 20021625 L NO20021625 L NO 20021625L NO 20021625 A NO20021625 A NO 20021625A NO 20021625 A NO20021625 A NO 20021625A NO 20021625 L NO20021625 L NO 20021625L
- Authority
- NO
- Norway
- Prior art keywords
- receptor antagonist
- synergistic combinations
- gaba
- structural analogue
- gaba structural
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Foreliggende oppfinnelse tilveiebringer metoder for behandling ved anvendelse av synergistiske kombinasjoner av en NKi-reseptor-antagonist og en GABA-analog og farmasøytiske preparater og produkter inneholdende NKrreseptorantagonisten og GABA-analogen. Foreliggende oppfinnelse tilveiebringer også anvendelse av en NKi-reseptorantagonist og en GABA- analog for fremstilling av et medikament for behandling eller forhindring av kronisk smerte.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15827199P | 1999-10-07 | 1999-10-07 | |
PCT/EP2000/009858 WO2001024792A1 (en) | 1999-10-07 | 2000-10-05 | Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20021625L true NO20021625L (no) | 2002-04-05 |
NO20021625D0 NO20021625D0 (no) | 2002-04-05 |
Family
ID=22567369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20021625A NO20021625D0 (no) | 1999-10-07 | 2002-04-05 | Synergistiske kombinasjoner av en NK1 reseptor antagonist og en GABA strukturell analog |
Country Status (38)
Country | Link |
---|---|
EP (2) | EP1221950B1 (no) |
JP (2) | JP2003510356A (no) |
KR (1) | KR20020060192A (no) |
CN (1) | CN1387434A (no) |
AP (1) | AP2002002501A0 (no) |
AR (1) | AR029646A1 (no) |
AT (1) | ATE269072T1 (no) |
AU (2) | AU7663300A (no) |
BG (1) | BG106548A (no) |
BR (1) | BR0014598A (no) |
CA (1) | CA2385930A1 (no) |
CO (1) | CO5280195A1 (no) |
CR (1) | CR6614A (no) |
CZ (1) | CZ20021116A3 (no) |
DE (1) | DE60011650T2 (no) |
DK (1) | DK1221950T3 (no) |
EA (1) | EA004266B1 (no) |
EE (1) | EE200200185A (no) |
ES (1) | ES2220542T3 (no) |
GT (1) | GT200000166A (no) |
HR (1) | HRP20020286A2 (no) |
HU (1) | HUP0203466A3 (no) |
IL (1) | IL148965A0 (no) |
IS (1) | IS6318A (no) |
MA (1) | MA26826A1 (no) |
MX (1) | MXPA02003484A (no) |
NO (1) | NO20021625D0 (no) |
NZ (1) | NZ517949A (no) |
OA (1) | OA12063A (no) |
PA (1) | PA8504301A1 (no) |
PE (1) | PE20010708A1 (no) |
PL (1) | PL357498A1 (no) |
PT (1) | PT1221950E (no) |
SK (1) | SK4542002A3 (no) |
TR (1) | TR200200913T2 (no) |
UY (1) | UY26376A1 (no) |
WO (2) | WO2001024792A1 (no) |
ZA (1) | ZA200202675B (no) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1094757C (zh) | 1996-07-24 | 2002-11-27 | 沃尼尔·朗伯公司 | 用于治疗疼痛的异丁基γ-氨基丁酸及其衍生物 |
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
EP1499309A4 (en) * | 2002-04-24 | 2008-05-28 | Cypress Bioscience Inc | PREVENTION AND TREATMENT OF FUNCTIONAL SOMATIC DISEASES, INCLUDING STRESS-BASED DISEASES |
US20060039968A1 (en) * | 2002-10-08 | 2006-02-23 | Ramalingam Manikandan | Gabapentin tablets and method for their preparation |
EP1721607A1 (en) * | 2003-03-21 | 2006-11-15 | Dynogen Pharmaceuticals, Inc. | Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators |
WO2004084880A1 (en) * | 2003-03-21 | 2004-10-07 | Dynogen Pharmaceuticals, Inc. | METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS |
WO2004084881A1 (en) * | 2003-03-21 | 2004-10-07 | Dynogen Pharmaceuticals, Inc. | METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS |
EP1543831A1 (en) * | 2003-12-18 | 2005-06-22 | Pfizer GmbH Arzneimittelwerk Gödecke | Pregabalin composition |
DE102007019071A1 (de) * | 2007-04-23 | 2008-10-30 | Ratiopharm Gmbh | Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin |
KR101786818B1 (ko) | 2010-07-30 | 2017-10-18 | 도레이 카부시키가이샤 | 신경장애성 동통의 치료제 또는 예방제 |
US9089531B2 (en) * | 2010-09-28 | 2015-07-28 | The Regents Of The University Of California | GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes |
WO2022234110A1 (en) * | 2021-05-07 | 2022-11-10 | Plus Vitech, S.L. | Gamma-aminobutyric acid derivatives for use in cancer therapy |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5025035A (en) * | 1990-10-12 | 1991-06-18 | Warner-Lambert Company | Method of treating depression |
US5792796A (en) * | 1994-07-27 | 1998-08-11 | Warner-Lambert Company | Methods for treating anxiety and panic |
US5510381A (en) * | 1995-05-15 | 1996-04-23 | Warner-Lambert Company | Method of treatment of mania and bipolar disorder |
JP2001502311A (ja) * | 1996-10-07 | 2001-02-20 | メルク シヤープ エンド ドーム リミテツド | 抗鬱及び/又は抗不安薬としてのcns浸透性nk―1受容体拮抗薬 |
AU729708B2 (en) * | 1996-12-02 | 2001-02-08 | Merck Sharp & Dohme Limited | Use of NK-1 receptor antagonists for treating severe anxiety disorders |
-
2000
- 2000-01-05 AP APAP/P/2002/002501A patent/AP2002002501A0/en unknown
- 2000-10-05 WO PCT/EP2000/009858 patent/WO2001024792A1/en not_active Application Discontinuation
- 2000-10-05 PT PT00966138T patent/PT1221950E/pt unknown
- 2000-10-05 SK SK454-2002A patent/SK4542002A3/sk unknown
- 2000-10-05 JP JP2001527791A patent/JP2003510356A/ja not_active Withdrawn
- 2000-10-05 CN CN00813906A patent/CN1387434A/zh active Pending
- 2000-10-05 EE EEP200200185A patent/EE200200185A/xx unknown
- 2000-10-05 AT AT00966138T patent/ATE269072T1/de not_active IP Right Cessation
- 2000-10-05 IL IL14896500A patent/IL148965A0/xx unknown
- 2000-10-05 CZ CZ20021116A patent/CZ20021116A3/cs unknown
- 2000-10-05 MX MXPA02003484A patent/MXPA02003484A/es active IP Right Grant
- 2000-10-05 EP EP00966138A patent/EP1221950B1/en not_active Expired - Lifetime
- 2000-10-05 BR BR0014598-0A patent/BR0014598A/pt not_active Application Discontinuation
- 2000-10-05 TR TR2002/00913T patent/TR200200913T2/xx unknown
- 2000-10-05 NZ NZ517949A patent/NZ517949A/en unknown
- 2000-10-05 KR KR1020027004462A patent/KR20020060192A/ko not_active Application Discontinuation
- 2000-10-05 ES ES00966138T patent/ES2220542T3/es not_active Expired - Lifetime
- 2000-10-05 OA OA1200200107A patent/OA12063A/en unknown
- 2000-10-05 EA EA200200303A patent/EA004266B1/ru not_active IP Right Cessation
- 2000-10-05 CA CA002385930A patent/CA2385930A1/en not_active Abandoned
- 2000-10-05 DK DK00966138T patent/DK1221950T3/da active
- 2000-10-05 AU AU76633/00A patent/AU7663300A/en not_active Abandoned
- 2000-10-05 DE DE60011650T patent/DE60011650T2/de not_active Expired - Fee Related
- 2000-10-05 PL PL00357498A patent/PL357498A1/xx not_active Application Discontinuation
- 2000-10-05 HU HU0203466A patent/HUP0203466A3/hu unknown
- 2000-10-06 CO CO00076105A patent/CO5280195A1/es not_active Application Discontinuation
- 2000-10-06 AR ARP000105296A patent/AR029646A1/es not_active Application Discontinuation
- 2000-10-06 PA PA20008504301A patent/PA8504301A1/es unknown
- 2000-10-06 PE PE2000001069A patent/PE20010708A1/es not_active Application Discontinuation
- 2000-10-06 GT GT200000166A patent/GT200000166A/es unknown
- 2000-10-06 UY UY26376A patent/UY26376A1/es not_active Application Discontinuation
- 2000-10-09 WO PCT/EP2000/010084 patent/WO2001024791A1/en not_active Application Discontinuation
- 2000-10-09 EP EP00979495A patent/EP1233766A1/en not_active Withdrawn
- 2000-10-09 JP JP2001527790A patent/JP2003510355A/ja not_active Withdrawn
- 2000-10-09 AU AU16962/01A patent/AU1696201A/en not_active Abandoned
-
2002
- 2002-03-21 IS IS6318A patent/IS6318A/is unknown
- 2002-03-22 BG BG106548A patent/BG106548A/xx unknown
- 2002-04-04 HR HR20020286A patent/HRP20020286A2/hr not_active Application Discontinuation
- 2002-04-05 ZA ZA200202675A patent/ZA200202675B/xx unknown
- 2002-04-05 NO NO20021625A patent/NO20021625D0/no not_active Application Discontinuation
- 2002-04-05 MA MA26587A patent/MA26826A1/fr unknown
- 2002-04-05 CR CR6614A patent/CR6614A/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL108007A (en) | USE OF AN INTERFERON-GAMMA (IFN-gamma) INHIBITOR IN THE PREPARATION OF A MEDICAMENT FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE | |
UA26213C2 (uk) | Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові | |
ATE418986T1 (de) | Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems welche einen nicotin-analog und einen acetylcholinesterase inhibitor enthalten | |
IS8807A (is) | Notkun á daptómýsíni og lyfjasamsetningar sem innihalda það | |
MX9602818A (es) | Un metodo de tratamiento de infeccion parasitaria usando antagonistas ige. | |
DE4497905T1 (de) | Pharmazeutische Zusammensetzung zur Prävention und Behandlung des Motion-Sickness-Syndroms | |
ATE265857T1 (de) | Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie | |
DE69736441D1 (de) | Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen | |
WO2001078698A3 (en) | Use of ngf-antagonists for the prevention or treatment of chronic visceral pain | |
BR9709915A (pt) | Composto composição farmacêutica utilização do composto e processos para o tratamento ou a prevençao de distúrbios fisiológicos asociados com um excesso de taquiquininas e para preparação do composto | |
DE69805973T2 (de) | Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase | |
HUP0001527A2 (hu) | Laktózmentes, nem higroszkópos és vízmentes dekarboetoxiloratadin-tartalmú gyógyászati készítmények | |
NO20021625L (no) | Synergistiske kombinasjoner av en NK1 reseptor antagonist og en GABA strukturell analog | |
CA2433785A1 (en) | Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof | |
EP0657167A3 (fr) | Application de l'oenothéine B pour obtenir un médicament destiné au traitement des troubles liés à l'hyperandrogénie, les compositions pharmaceutiques le contenant et un procédé de préparation à partir d'Epilobium Parviflorum. | |
DE69822810D1 (de) | Somatostatin und somatostatin agoniste zur behandlung der insulinsunempfindlichkeit und syndrome x | |
EP0744176A3 (en) | Methods for inhibiting bone loss | |
BR9812531A (pt) | Combinação de componentes, preparação farmacêutica, produção desta, e, uso da combinação ou da preparação farmacêutica | |
ATE254595T1 (de) | 2-amino-6-methyl-7-acetyl-tetralin und pharmazeutische zusammensetzungen zur vorbeugung und therapeutischen behandlung von entzündlichen und/oder autoimmunkrankheiten | |
HUP0000110A2 (hu) | Azaciklusos, azabiciklusos vagy tetrahidropiridinszármazékokat tartalmazó, fájdalom kezelésére alkalmas gyógyászati készítmények | |
EP0743068A3 (en) | Composition for inhibiting bone loss containing vanadyl sulfate | |
CY2499B1 (en) | Use of nk-1 receptor antagonists for treating stress disorders. | |
HUP9903375A2 (hu) | Olanzapint és fájdalomcsillapító hatóanyagot tartalmazó szinergista hatású gyógyszerkészítmények | |
EP0564216A3 (en) | Pharmaceutical compositions for the treatment and/or prevention of degenerative disorders in the retina | |
EP0384302A3 (en) | Use of ubenimex in the manufacture of a medicament for treating myelodysplastic syndrome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |